Table 4 Best response in patients with/without liver metastasis
From: Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
| Â | Gefitinib/Erlotinib | Afatinib | Osimertinib | |||
|---|---|---|---|---|---|---|
Liver metastasis + n (%) | Liver metastasis- n (%) | Liver metastasis + n (%) | Liver metastasis- n (%) | Liver metastasis + n (%) | Liver metastasis- n (%) | |
Total a | 14 | 156 | 3 | 49 | 15 | 119 |
Best Response | ||||||
 CR | 0 (0.0) | 17 (10.9) | 0 (0.0) | 5 (10.2) | 0 (0.0) | 5 (4.2) |
 PR | 8 (57.1) | 91 (58.3) | 2 (66.7) | 24 (48.9) | 8 (53.3) | 86 (72.3) |
 SD | 2 (14.3) | 36 (23.1) | 0 (0.0) | 15 (30.6) | 4 (26.7) | 22 (18.5) |
 PD | 4 (28.6) | 12 (7.7) | 1 (33.3) | 5 (10.2) | 3 (20.0) | 6 (5.0) |
ORR | 8 (57.1) | 108 (69.2) | 2 (66.7) | 29 (59.2) | 8 (53.3) | 91 (76.5) |
DCR | 10 (71.4) | 144 (92.3) | 2 (66.7) | 44 (89.8) | 12 (80.0) | 113 (95.0) |